These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 11365225

  • 1. Building your body to survive: the use of anabolic steroids for HIV therapy.
    Vergel N.
    Posit Aware; 1998; 9(2):37-41. PubMed ID: 11365225
    [Abstract] [Full Text] [Related]

  • 2. Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting.
    Gold J, Batterham MJ, Rekers H, Harms MK, Geurts TB, Helmyr PM, Silva de Mendonça J, Falleiros Carvalho LH, Panos G, Pinchera A, Aiuti F, Lee C, Horban A, Gatell J, Phanuphak P, Prasithsirikul W, Gazzard B, Bloch M, Danner SA, E-1696 Study Investigators.
    HIV Med; 2006 Apr; 7(3):146-55. PubMed ID: 16494628
    [Abstract] [Full Text] [Related]

  • 3. The use of testosterone in the AIDS wasting syndrome.
    Corcoran C, Grinspoon S.
    AIDS Clin Care; 1999 Apr; 11(4):25-6, 33-4. PubMed ID: 11366208
    [Abstract] [Full Text] [Related]

  • 4. Testosterone replacement, weight lifting help wasting.
    AIDS Alert; 1996 Jun; 11(6):suppl 1-2. PubMed ID: 11363546
    [Abstract] [Full Text] [Related]

  • 5. Comparing Oxandrin and Anadrol-50.
    Vazquez E.
    Posit Aware; 1998 Jun; 9(4):49-51. PubMed ID: 11365632
    [Abstract] [Full Text] [Related]

  • 6. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting.
    Hengge UR, Stocks K, Wiehler H, Faulkner S, Esser S, Lorenz C, Jentzen W, Hengge D, Goos M, Dudley RE, Ringham G.
    AIDS; 2003 Mar 28; 17(5):699-710. PubMed ID: 12646793
    [Abstract] [Full Text] [Related]

  • 7. Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.
    Mulligan K, Zackin R, Clark RA, Alston-Smith B, Liu T, Sattler FR, Delvers TB, Currier JS, AIDS Clinical Trials Group 329 Study Team, National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group.
    Arch Intern Med; 2005 Mar 14; 165(5):578-85. PubMed ID: 15767536
    [Abstract] [Full Text] [Related]

  • 8. Anabolic steroids in COPD: a review and preliminary results of a randomized trial.
    Sharma S, Arneja A, McLean L, Duerksen D, Leslie W, Sciberras D, Lertzman M.
    Chron Respir Dis; 2008 Mar 14; 5(3):169-76. PubMed ID: 18684793
    [Abstract] [Full Text] [Related]

  • 9. Testosterone replacement for hypogonadism: clinical findings and best practices.
    Hengge UR.
    AIDS Read; 2003 Dec 14; 13(12 Suppl):S15-21. PubMed ID: 14959695
    [Abstract] [Full Text] [Related]

  • 10. Approaches to the AIDS Wasting Syndrome.
    Corcoran C.
    Posit Dir News; 1998 Dec 14; 10(2):24-7. PubMed ID: 11365549
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Anabolic therapy in patients with HIV infections].
    Gruzdev BM, Ivannikov EV, Gorbacheva ES.
    Ter Arkh; 1999 Dec 14; 71(11):35-7. PubMed ID: 10626332
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Catamnestic results following therapy of heart patients with anabolic steroids].
    Fiegel G, Bargheer R.
    Med Klin; 1966 Nov 25; 61(47):1870-2. PubMed ID: 5989967
    [No Abstract] [Full Text] [Related]

  • 15. New tool assesses effectiveness of nutritional intervention.
    Bouvier G.
    Fac Notes (New Orleans La); 1998 Nov 25; 10(2):10. PubMed ID: 11365125
    [Abstract] [Full Text] [Related]

  • 16. No attrition in research on wasting therapies.
    Gilden D.
    GMHC Treat Issues; 1997 Nov 25; 11(4/5):9, 12-6. PubMed ID: 11364378
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Use of bioelectrical impedance analysis to determine body composition changes in HIV-associated wasting.
    Klauke S, Fischer H, Rieger A, Frühauf L, Staszewski S, Althoff PH, Helm EB.
    Int J STD AIDS; 2005 Apr 25; 16(4):307-13. PubMed ID: 15899085
    [Abstract] [Full Text] [Related]

  • 19. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids.
    Lane HA, Grace F, Smith JC, Morris K, Cockcroft J, Scanlon MF, Davies JS.
    Eur J Clin Invest; 2006 Jul 25; 36(7):483-8. PubMed ID: 16796605
    [Abstract] [Full Text] [Related]

  • 20. Soluble tumour necrosis factor alpha receptor 2, a serum marker of resistance to the anabolic actions of growth hormone in subjects with HIV disease.
    Gelato MC, Mynarcik D, McNurlan MA.
    Clin Sci (Lond); 2002 Jan 25; 102(1):85-90. PubMed ID: 11749664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.